

**PCR-/NAT VRE
(RV 546) Mai 2024**



Tabelle 1: Probenzusammensetzung und erwartetes Ergebnis.

Sample composition and expected results.

Proben Nr.	Erwartet / expected	Probenzusammensetzung / Sample composition	
546A 240521 01	+++	61 / 71	<i>Enterococcus faecalis vanA</i> (~ 2x10 ⁵ CFU/mL)
546A 240521 02	Ø	62	<i>Escherichia coli K12</i>
546A 240521 03	Ø	62	<i>E. faecium vanA/vanB neg</i> (~ 1x10 ⁶ CFU/mL)
546A 240521 04	+++/ +	61 / 72	<i>E. faecalis vanA/vanB neg</i> (~ 5x10 ⁵ CFU/mL) <i>E. casseliflavus vanB</i> (~ 5x10 ³ CFU/mL)

Tabelle 2: Häufigkeit der Mitteilung verschiedener Befunde.

Absolute numbers of reported individual results.

n = 76		Proben Nr. (Sample no.)			
Befund Result	01	02	03	04	
Positiv	76	0	0	69	
Negativ	0	76	76	6	
Fraglich Questionable	0	0	0	1	

	Inhibition			
	01	02	03	04
n.d.	1	1	1	1
nein no	75	75	75	75
ja yes	0	0	0	0

Tabelle 3: Häufigkeit richtig positiver und richtig negativer NAT-Befunde bei Anwendern verschiedener Methoden.

Absolute numbers and relative frequency of reported true positive and true negative results among various NAT methods.

NAT-Methode [Code] (total number *)	NAT richtig positiv True positive results				NAT richtig negativ True negative results			
	01		04		02		03	
	Absolut Absolute	%	Absolut Absolute	%	Absolut Absolute	%	Absolut Absolute	%
Amplex eazyplex VRE (n = 2)	2	100	1	50	2	100	2	100
Amplex eazyplex VREbasic (n = 4)	4	100	1	25	4	100	4	100
AmpliGnost Vancomycin A/B (n = 3)	3	100	3	100	3	100	3	100
BioGx Vancomycin resistance (n = 1)	1	100	0	0	1	100	1	100
Bruker-HAIN GenoType Enteroc. (n = 12)	12	100	11 [§]	100	12	100	12	100
Cepheid Xpert vanA / vanB (n = 25)	25	100	25	100	25	100	25	100
ampliCube MDR Panel1-6 (n = 1)	1	100	1	100	1	100	1	100
Seegene Allplex Entero-DR (n = 10)	10	100	10	100	10	100	10	100

TIB Molbiol LightMix Kit (n = 1)	1	100	1	100	1	100	1	100
In house PCR assay (n = 15)	15	100	14	93	15	100	15	100
Other commercial tests (n = 2)	2	100	2	100	2	100	2	100

§ Fraglich Due to reporting questionable results, the number of true results has been reduced.

Comments:

1. Seventy-five participants reported dedicated vanA / vanB identification. Except one laboratory, all reported results were correct
2. The following tests are listed under "Other commercial tests": CerTest VIASURE Vancomycin resistance Real Time PCR Detection Kit (1x) and GeneProof VRE (1x).